- On March 18, 2026, Core Scientific, Inc. entered into an amendment to its Delayed-Draw Bridge Credit Agreement, increasing total term loan commitments by US$500.0 million to US$1.0 billion and drawing the full incremental amount on the closing date.
- This substantial expansion of borrowing capacity materially alters Core Scientific’s financial flexibility, potentially affecting how it funds high‑performance computing projects and manages its evolving capital structure.
- We’ll now examine how this expanded US$1.0 billion credit facility could reshape Core Scientific’s investment narrative built around HPC growth.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it. Find the list for free.
Core Scientific Investment Narrative Recap
To own Core Scientific, you need to believe its shift from Bitcoin mining toward high performance computing can eventually offset past losses and concentration risk around CoreWeave. The new US$1.0 billion bridge facility meaningfully lifts financial flexibility, but it also increases leverage, which could amplify the impact of any delays in ramping HPC contracts or setbacks in improving profitability over the next few quarters.
The most relevant recent announcement is the expanded CoreWeave agreement, which now targets close to 900 MW of contracted HPC capacity. That deal underpins the current growth story, and the fresh US$500.0 million term loan draw gives Core Scientific more room to build out data centers and meet its obligations under this contract, even as investors weigh the trade off between higher capacity and a still loss making full year 2025.
Yet beneath this funding boost, one risk investors should be aware of is...
Read the full narrative on Core Scientific (it's free!)
Core Scientific's narrative projects $1.4 billion revenue and $439.9 million earnings by 2029. This requires 62.4% yearly revenue growth and a $720.6 million earnings increase from -$280.7 million today.
Uncover how Core Scientific's forecasts yield a $26.40 fair value, a 63% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already modeling revenue of about US$1.8 billion and earnings near US$641.5 million by 2028, so if you worry about overcapacity and CoreWeave reliance, it is worth recognizing how different your view might be from that bullish narrative and asking how this new US$1.0 billion facility could shift expectations on both sides.
Explore 3 other fair value estimates on Core Scientific - why the stock might be worth just $26.40!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Core Scientific research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- Our free Core Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Core Scientific's overall financial health at a glance.
Looking For Alternative Opportunities?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com